Annual Meeting, James Song, MD, chief medical officer and director of clinical research, Frontier Dermatology, outlines maj ...

All-urban residence correlated with longer treatment initiation times despite an a priori hypothesis favoring rural delays, suggesting urban-system bottlenecks rather than geographic distance alone.

Social Vulnerability Index scores inversely correlated with dietary fiber intake, suggesting social determinants may shape diet patterns relevant to microbiome-associated immunotherapy response. Whole ...

A new real-world analysis suggests that cardio-kidney-metabolic (CKM) therapies, widely used in type 2 diabetes (T2D), may offer meaningful kidney benefits for patients with type 1 diabetes (T1D) and ...

Following enhanced credit expiration, 80% of continuing Marketplace enrollees reported higher cost sharing year over year, and 51% said costs were “a lot higher.” Financial toxicity concerns were ...

One in 4 Medicaid managed care organization sanctions are not remediated, revealing inconsistent state and federal oversight and the need to standardize CMS reporting and enforcement guidelines.

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP. She also explained how the ...

Linerixibat targets pruritus pathobiology in PBC by blocking ileal bile acid reuptake, aiming to lower circulating pruritogenic bile acid–related mediators. GLISTEN demonstrated greater 24-week WI-NRS ...

A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ustekinumab under standard induction and q12w maintenance dosing. Durability through ...

Sanctions are a key tool that states use to hold Medicaid managed care organizations (MCOs) accountable for their use of public funds. The 2023 reports that MCOs submit ...

In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists ...

Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...